Clinical Core

亚利桑那州ADCC的临床核心是由六个招聘网站(班纳阿尔茨海默病研究所、巴罗神经学研究所、亚利桑那州梅奥诊所、班纳·孙健康研究所以及亚利桑那大学健康科学中心和退伍军人医学中心)组成的联合体，在全州范围内提供集聚地区，在单一临床核心主任的领导下作为一个标准化单位发挥作用。临床核心保持一个 目标：500名老年痴呆症患者，包括325名正常对照组、75名轻度认知障碍(MCI)患者和100名阿尔茨海默病(AD)及其他形式的退行性痴呆症患者。在这些诊断类别中嵌入了定义为拉丁裔和美洲原住民的队列。临床核心利用我们的多机构诊断共识会议， 集中化的数据管理计划，并与其他每个核心建立密切的工作关系。所有受试者都要接受标准化诊断测试：1)满足严格的入学标准；2)包括人口统计、历史、医学、神经学、精神病学、神经心理学和遗传学指标；3)纳入NACC统一数据集(UDS)；4)采用对文化敏感的测试程序。 符合登记条件的患者和完成年度随访的患者在两周一次的诊断共识会议上进行了讨论。所有人都在进入时接受载脂蛋白E(APOE)基因分型，并在所有地点进行一年一度的标准化神经心理学测试。对患者参加正在进行的研究项目的资格和参与情况进行跟踪和持续审查。所有人都可以在大脑中注册 捐赠计划，用于确认临床诊断的神经病理学，尽管对文化敏感的多样性亚群(拉丁裔和美洲原住民)的成员不需要脑捐赠。对老年正常对照组进行纵向研究的辅助项目也通过其他资助机制获得NACC UDS的支持。这些队列提供了独特的机会来研究AD不同风险人群的认知正常和MCI之间的转变，并利用我们在成像、基因组学、认知神经科学和其他研究方法方面的优势。为了实现ADCC的目标，来自独立资助项目的主题和数据现在可以作为资源提供给其他 研究人员在其他研究中使用，并将使用UDS进行前瞻性跟踪。

The Clinical Core of the Arizona ADCC is a consortium of six recruitment sites (Banner Alzheimer Institute, Barrow Neurological Institute, Mayo Clinic Arizona, Banner Sun Health Research Institute, and the University of Arizona Health Sciences Center and VA medical Center) providing catchment areas throughout the state that function as a standardized unit under a single Clinical Core Director. The Clinical Core maintains a target of 500 participants at all stages of the aging-dementia spectrum including 325 normal controls, 75 patients with mild cognitive impairment (MCI), and 100 with Alzheimer's disease (AD) and other forms of degenerative dementia. Embedded within these diagnostic categories are defined Latino and Native American cohorts. The Clinical Core capitalizes on our multi-institutional diagnostic consensus conference, centralized data management program, and close working relationships with each of the other Cores. All subjects undergo standardized diagnostic testing that: 1) fulfills strict entrance criteria; 2) includes demographic, historical, medical, neurological, psychiatric, neuropsychological, and genetic measures; 3) incorporates the NACC Uniform Data Set (UDS); and 4) employs culturally sensitive test procedures. Patients eligible for enrollment and those completing annual follow-up are discussed in a biweekly diagnostic consensus conference. All undergo apolipoprotein E (APOE) genotyping at entry, and an annual standardized neuropsychological battery of tests at all sites. Patient eligibility for and participation in ongoing research projects is tracked and reviewed on an ongoing basis. All are offered enrollment in the Brain Donation Program for neuropathological confirmation of clinical diagnoses, though brain donation is not required of members of culturally sensitive diversity subgroups (Latino and Native Americans). Ancillary programs of longitudinally studied aging normal controls also receive the NACC UDS supported through other funding mechanisms. These cohorts provide unique opportunities to study the transition between cognitive normality and MCI in persons at differential risk for AD and to capitalize on our strengths in maging, genomics, cognitive neuroscience, and other research methods. To address the goals of the ADCC, subjects and data from independently funded projects are now available as a resource to other researchers, being used in other studies, and will be followed prospectively using the UDS.